ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026
Recombinant Protein Drugs: A 2025 Update.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Over the past decade, recombinant protein therapeutics have moved from conventional biologics toward highly engineered, multifunctional versions. Enabled by innovations in synthetic biology, host cell engineering, and bioprocess optimization, proteins are increasingly viewed not only as drugs for replacement therapies but also as fully versatile platforms in innovative therapeutic approaches aiming at functional reprogramming. Advances in host systems, from optimized microbial strains to mammalian and plant-based platforms, have expanded the range of proteins that can be produced with high fidelity, scalability, and safety. In parallel, modular protein engineering has delivered next-generation formats, including bispecific antibodies, nanobodies, fusion proteins, and self-assembling biomaterials, broadening therapeutic applications across oncology, inflammation, metabolic disorders, and beyond. At the same time, regulatory frameworks are adapting to support accelerated approval of personalized and complex biologics, while decentralized and flexible manufacturing models begin to emerge. This review provides a 2025 update on the field of recombinant protein drugs, integrating advances in production platforms, protein engineering, and regulatory science, and outlining how these technologies are shaping the next generation of biologics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.